State Street Holds 4.8% Of Avalo Without Seeking To Influence Its Control

The holding covered September 30, 2026, and included shared voting authority over 2,490,708 shares.

Share
State Street Holds 4.8% Of Avalo Without Seeking To Influence Its Control

State Street held a 4.8% stake in Avalo Therapeutics, which develops treatments for immune-mediated inflammatory diseases, as of September 30, 2026, according to a passive ownership disclosure filed Tuesday with the SEC. State Street certified that the investment was part of its ordinary business and was not intended to influence or change Avalo's control.

Voting Power Covers 2,490,708 Shares

State Street reported 2,563,226 common shares and shared authority to sell or otherwise dispose of the entire holding. Its shared voting authority covered 2,490,708 shares; it reported no sole voting authority.

The ownership disclosure also named SSGA Funds Management, State Street Global Advisors Europe, State Street Global Advisors Limited, State Street Global Advisors Trust Company and State Street Global Advisors, Ltd.

Avalo's Lead Drug Is In Testing

Avalo's research focuses on blocking IL-1β, a protein involved in inflammation. Its lead candidate, abdakibart, also called AVTX-009, is an antibody in a mid-stage trial for hidradenitis suppurativa, a chronic inflammatory skin disease.

The Avalo-sponsored trial covers approximately 250 adults with moderate to severe disease, with sites in the United States, Canada, Australia, Turkey and several European countries. Avalo holds an exclusive worldwide license to abdakibart from Eli Lilly.

Avalo has no products approved for sale and relies on contract manufacturers rather than operating manufacturing facilities. Its older drug programs are outside clinical development.

Sources

More on Avalo Therapeutics

All Avalo Therapeutics (AVTX) coverage →